The US Food and Drug Administration (US FDA) has given its final
approval to Aurobindo Pharma Ltd. for 5mg and 10mg Donepezil Hydrochloride
These tablets are generically equivalent to Aricept tablets (sold
by Eisai Medical Research Inc. in partnership with Pfizer) and fall under the
Central Nervous System therapeutic segment that are meant for the treatment of
mild, moderate and severe dementia and Alzheimer's disease.
The product had a market size of approximately USD 2.5 billion
for the twelve months ended September 2010, according to IMS.